Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.11779/843| Title: | Real-world comparison of major bleeding risk among untreated non-valvular atrial fibrillation patients and those initiating apixaban, dabigatran, rivaroxaban, or warfarin | Authors: | Amin, Alpesh Keshishian, A Xie, L Başer, Onur Price, K Vo, L Mardekian, J Mendoza, M Singhal, S Patel, C Odell, K Trocio J. |
Source: | Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Mardekian J, Mendoza M, Singhal S, Patel C, Odell K, Trocio J. (April 2-4, 2016). Real-world comparison of major bleeding risk among untreated non-valvular atrial fibrillation patients and those initiating apixaban, dabigatran, rivaroxaban, or warfarin. American College of Cardiology (ACC) 65th Annual Scientific Session & Expo. San Diego, CA. | Abstract: | Background: Recent large randomized controlled trials have shown that novel oral anticoagulants (NOACs) are at least as effective as warfarin for risk reduction of stroke in patients with non-valvular atrial fibrillation (NVAF) and are associated with similar or lower rates of bleeding. The study aim was to compare major bleeding risk among untreated NVAF patients to those initiating apixaban, dabigatran, rivaroxaban or warfarin | Description: | Onur Başer (MEF Author) | URI: | https://hdl.handle.net/20.500.11779/843 |
| Appears in Collections: | Ekonomi Bölümü Koleksiyonu |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Real.pdf Until 2089-02-11 | Konferans Dosyası | 400.87 kB | Adobe PDF | View/Open Request a copy |
CORE Recommender
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.